Document is current
Any future updates will be listed below
-
Authors
Amato, Luisa
De Rosa, Caterina
Di Guida, Gaetano
Sepe, Filippo
Ariano, Annalisa
Capaldo, Sara
Ul Haq, Faiz
Di Liello, Alessandra
Tuccillo, Concetta
Lucà, Stefano
Franco, Renato
De Rosa, Viviana
Iommelli, Francesca
Servetto, Alberto
Ciardiello, Fortunato https://orcid.org/0000-0002-4661-5540
Della Corte, Carminia Maria https://orcid.org/0000-0002-3396-8099
Morgillo, Floriana
-
Funding
Funding for this research was provided by:
Fondazione Italiana per la Ricerca sul Cancro (26237)
- License Information
-
More Information
Article History
Received: 4 December 2024
Revised: 31 March 2025
Accepted: 4 April 2025
First Online: 13 April 2025
Competing interests
: FM: receipt of honoraria or consultation fees for speaker, consultancy, or advisory roles: Roche, Servier, Incyte, ESMO and MSD. FC: receipt of honoraria or consultation fees for speaker, consultancy, or advisory roles: Amgen, Merck KGaA, MSD, Pierre Fabre, Pfizer, Roche Servier; institutional financial interests, financial support for clinical trials or contracted research; Amgen, Merck KGaA, MSD, Pierre Fabre, Pfizer, Roche, Servier. CMDC: reported receiving personal fees from Roche, MSD and AstraZeneca, and travel grants from Amgen outside the submitted work. The remaining authors have no conflicts of interest to declare.
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University of Campania “Luigi Vanvitelli”, Naples (n. 280 on 16 May 2020).
: Informed consent was obtained from all subjects involved in the study.
